Company intelligence / Profile preview
AnHorn Medicines
Taipei City, Taiwananhornmed.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
AnHorn Medicines has advanced its lead program, AH‑001—a topical small molecule protein degrader targeting the androgen receptor—into Phase 1 clinical trials for androgenetic alopecia. Preclinical data showed efficacy in reversing DHT-induced hair loss with a favorable safety profile due to local administration. The company’s broader pipeline leverages its proprietary protein degradation platform to address cancers and other diseases. Series A funding ($10M) was completed in April 2023 to accelerate development. No additional clinical results are publicly available yet.
- Therapeutic areas
- OncologyRare DiseasesDermatology
- Modalities
- Small moleculesProtein degraders
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
Investors include Taiwania CapitalTaiAn TechnologiesIndustrial Technology Investment CorporationHong Tai Electric IndustrialBlack Marble Capital ManagementMega Venture CapitalSunplus Technology.
Beyond the preview
Go deeper on AnHorn Medicines.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AnHorn Medicines.